Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.
Teicher BA, Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Monks A, Morris J. Teicher BA, et al. Among authors: harris e. Mol Cancer Ther. 2015 Nov;14(11):2452-62. doi: 10.1158/1535-7163.MCT-15-0074. Epub 2015 Sep 8. Mol Cancer Ther. 2015. PMID: 26351324 Free PMC article.
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
Polley E, Kunkel M, Evans D, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Connelly J, Harris E, Fer N, Sonkin D, Kaur G, Monks A, Malik S, Morris J, Teicher BA. Polley E, et al. Among authors: harris e. J Natl Cancer Inst. 2016 May 31;108(10):djw122. doi: 10.1093/jnci/djw122. Print 2016 Oct. J Natl Cancer Inst. 2016. PMID: 27247353 Free PMC article.
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.
Monks A, Zhao Y, Hose C, Hamed H, Krushkal J, Fang J, Sonkin D, Palmisano A, Polley EC, Fogli LK, Konaté MM, Miller SB, Simpson MA, Voth AR, Li MC, Harris E, Wu X, Connelly JW, Rapisarda A, Teicher BA, Simon R, Doroshow JH. Monks A, et al. Among authors: harris e. Cancer Res. 2018 Dec 15;78(24):6807-6817. doi: 10.1158/0008-5472.CAN-18-0989. Epub 2018 Oct 24. Cancer Res. 2018. PMID: 30355619 Free PMC article.
Exposure time versus cytotoxicity for anticancer agents.
Evans DM, Fang J, Silvers T, Delosh R, Laudeman J, Ogle C, Reinhart R, Selby M, Bowles L, Connelly J, Harris E, Krushkal J, Rubinstein L, Doroshow JH, Teicher BA. Evans DM, et al. Among authors: harris e. Cancer Chemother Pharmacol. 2019 Aug;84(2):359-371. doi: 10.1007/s00280-019-03863-w. Epub 2019 May 17. Cancer Chemother Pharmacol. 2019. PMID: 31102023 Free PMC article.
ATR inhibition reverses the resistance of homologous recombination deficient MGMTlow/MMRproficient cancer cells to temozolomide.
El Touny LH, Hose C, Connelly J, Harris E, Monks A, Dull AB, Wilsker DF, Hollingshead MG, Gottholm-Ahalt M, Alcoser SY, Mullendore ME, Parchment RE, Doroshow JH, Teicher BA, Rapisarda A. El Touny LH, et al. Among authors: harris e. Oncotarget. 2021 Oct 12;12(21):2114-2130. doi: 10.18632/oncotarget.28090. eCollection 2021 Oct 12. Oncotarget. 2021. PMID: 34676045 Free PMC article.
Elucidation of thioredoxin as a molecular target for antitumor quinols.
Bradshaw TD, Matthews CS, Cookson J, Chew EH, Shah M, Bailey K, Monks A, Harris E, Westwell AD, Wells G, Laughton CA, Stevens MF. Bradshaw TD, et al. Among authors: harris e. Cancer Res. 2005 May 1;65(9):3911-9. doi: 10.1158/0008-5472.CAN-04-4141. Cancer Res. 2005. PMID: 15867391
Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases.
Lu J, Risbood P, Kane CT Jr, Hossain MT, Anderson L, Hill K, Monks A, Wu Y, Antony S, Juhasz A, Liu H, Jiang G, Harris E, Roy K, Meitzler JL, Konaté M, Doroshow JH. Lu J, et al. Among authors: harris e. Biochem Pharmacol. 2017 Nov 1;143:25-38. doi: 10.1016/j.bcp.2017.07.007. Epub 2017 Jul 11. Biochem Pharmacol. 2017. PMID: 28709950 Free PMC article.
3,496 results